Ab#22 ASCO #GU25 by Dr. Tamim Niazi👉bit.ly/4hMu4KE👉Randomized ph2 study of MDT in oligometastatic CRPC #prostatecancer👉addition of SBRT to SOC doubled the median rPFS (& delayed time to next Rx)👇#ScottTyldesley OncoAlert UroToday.com PCF Science

ASCO24 Updates: Dr. April Rose on BEAVER Trial and New BRAF Cancer Therapies April Rose ASCO JGH Foundation | Fondation HGJ OncoDaily covered the ASCO Annual Meeting in Chicago, where we had the opportunity to interview Dr. April Rose from Jewish General Hospital. She discussed the BEAVER

I am so excited to be a part of the team - led by Dr. Cristiano Ferrario - that is bringing this clinical trial with a promising new type of immunotherapy to prostate cancer patients in Montreal :) A first in Canada!

Une nouvelle étude mené par Hannah Garner (ICG), montre que les précurseures des #neutrophiles reçoivent des signaux des tumeurs mammaires et favorisent les #métastases. Collaboration avec le The Netherlands Cancer Institute, Moreno Martinovic, Karin de Visser and deWitLab. Détails: tinyurl.com/4b5n5psu

Yesterday we had to say good bye to Morty. She was the goodest girl. She loved swimming and good food. She was very patient and gentle. She gave us 16 wonderful years and she will forever be missed.

The remarkable benefit of exercise was just extended to improved survival after cancer in a randomized trial NEJM #ASCO25 nejm.org/doi/full/10.10…

#ASCO25 I bring it up in every single patient I see with colorectal and other cancers. Good to see growing data in this space.👏🏽 🏃‍♂️ OncoAlert

The #CO21 CHALLENGE trial results were presented today at #ASCO25 annual meeting - the groundbreaking study is the first to conclusively answer a long-standing question in oncology: Can physical activity improve cancer survival? buff.ly/frfHTDz

Substudy G of CCTG IND.234 PC_BETS (V)—A ctDNA–directed phase II study of carboplatin in patients with previously treated #mCRPC. Presented by April Rose, MD, PhD, FRCPC McGill University. #ASCO25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4kjbviZ

If you are at #ASCO25 come check out Michael Ong present substudy C of the CCTG PC-BETS trial. Darolutamide for mCRPC with AR alterations based on ctDNA (Alex Wyatt)

Come check out Sebastien Hotte present substudy F (durva tremi) of the CCTG PC-BETS trial for mCRPC pts who are biomarker positive or negative (based on ctDNA (Alex Wyatt )

Really honoured to get to collaborate on this CCTG PC-BETS study. and to present substudy G at #ASCO25 - carboplatin for mCRPC with DDR alterations detected in ctDNA (Alex Wyatt)

If you’re at #ASCO25 stop by poster 432 to chat with Islam Elkholi about his work on non-V600 BRAF mutant cancers!

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

🟣 Nouvelle de dernière heure La grande Chantal Hébert vient de recevoir l’Ordre national du Québec, la plus haute distinction honorifique de la province. 🎙️ Journaliste politique hors pair. 🖋️ Chroniqueuse redoutablement lucide. 🇨🇦 Voix incontournable dans le débat canadien.

🟣 Breaking News Chantal Hébert has just been awarded the National Order of Quebec, the province’s highest honour. 🎙️ A brilliant political journalist 🖋️ A fiercely insightful columnist 🇨🇦 An essential voice in Canada’s public discourse Her sharp analysis, intellectual

Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 OncoAlert UroToday.com PCF Science